IRCT2017082117756N24 IRCT 2017-09-10 Vice-chancellery of Research, Birjand University of Medical Sciences Effects of tissue plasminogen activator and dual antiplatelet therapy in acute ischemic stroke treatment - A comparative study of the effects of tissue plasminogen activator and dual antiplatelet therapy on improvement of the score of the National Institutes of Health Stroke Scale in acute ischemic stroke treatment 2017-03-21 anticipated 60 Complete https://irct.ir/trial/16264 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: This is a double-blind study and both the physician and the patient are unaware of the study groups. Moreover, the participants will be selected via convenience sampling method and assigned into intervention and control groups via randomized blocked allocation method (i.e., 1:1). 2 acute ischemic stroke. Intervention 1: Intervention Group (tissue plasminogen activator ): The cases receive tissue plasminogen activator (Retavase®) 0.9 milligram per kilogram (maximum doses: 90 milligram) where 10 percent of the total dose is administered as a 10 U bolus dose followed by a 60-minute infusion of the remaining doses. Clinical response will be assessed at the initial presentation, after 24 and 48 hours, and at discharge from hospital by national institutes of health stroke scale. Decrease in score of national institutes of health stroke scale will be considered as the sign of improvement. Intervention 2: Control Group (dual antiplatelet therapy): The controls receive dual antiplatelet therapy by daily aspirin 80 milligram and clopidogrel 75 milligram for three months. After three months, the clopidogrel will be discontinued. Clinical response will be assessed at the first presentation, after 24 and 48 hours and at discharge from hospital by national institutes of health stroke scale. Decrease in score of national institutes of health stroke scale will be considered as the sign of improvement.